Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review

Table 3 Coronavirus disease 2019 patients treated with tocilizumab and corticosteroids

Ref.	Tocilizumab group	Control
Salama et al[110], RCT	80.3%	87.5%
Rosas et al[113], RCT	36.1%	54.9%
Stone et al[90], RCT	11%	6%
Salvarani et al[111], RCT	10%	7.6%
Mariette et al[112], RCT	33%	61%
RECOVERY Collaborative Group[115], RCT	82%	82%
REMAP-CAP Investigators et al[116], RCT	> 80%
Veiga et al[114], RCT	69%	73%
Gupta et al[189], observational	18.7%	12.6%
Somers et al[108], observational	29%	20%
Fisher et al[109], observational	73.3%	78.6%
Biran et al[102], observational	46%	42%
Guaraldi et al[101], observational	30%	17%
Rossotti et al[105], observational	Not reported
Rojas-Marte et al[107], observational	43%	33%

RCT: Randomized clinical trial.